XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) - EUR (€)
€ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Profit or loss [abstract]        
Revenue € 35,998 € 47,393 € 131,892 € 80,982
Cost of sales 11,465 12,929 19,034 17,551
Gross profit 24,533 34,464 112,858 63,431
Research and development costs 83,478 105,021 154,165 211,134
Selling, general and administrative expenses 74,312 70,281 141,095 136,820
Operating profit/(loss) (133,257) (140,838) (182,402) (284,523)
Share of profit/(loss) of associates (5,322) (7,451) (11,118) (8,677)
Finance income 49,052 35,761 14,395 80,374
Finance expenses 19,624 9,334 58,553 18,652
Profit/(loss) before tax (109,151) (121,862) (237,678) (231,478)
Income taxes/(expenses) (229) 429 (2,737) (868)
Net profit/(loss) for the period (109,380) (121,433) (240,415) (232,346)
Attributable to owners of the Company € (109,380) € (121,433) € (240,415) € (232,346)
Basic earnings/(loss) per share € (1.91) € (2.16) € (4.21) € (4.14)
Diluted earnings/(loss) per share € (1.91) € (2.16) € (4.21) € (4.14)
Number of shares used for calculation (basic and diluted) [1] 57,345,613 56,218,257 57,114,435 56,155,441
Statement of comprehensive income [abstract]        
Net profit/(loss) for the period € (109,380) € (121,433) € (240,415) € (232,346)
Items that may be reclassified subsequently to profit or (loss):        
Exchange differences on translating foreign operations 15 (1,016) 78 (1,803)
Other comprehensive income/(loss) for the period, net of tax 15 (1,016) 78 (1,803)
Total comprehensive income/(loss) (109,365) (122,449) (240,337) (234,149)
Attributable to owners of the Company € (109,365) € (122,449) € (240,337) € (234,149)
[1] As of June 30, 2024 and June 30, 2023, a total of 6,107,875 and 6,866,241 warrants outstanding, respectively, each carrying the right to subscribe for one ordinary share, and 575,000 convertible senior notes which can potentially be converted into 3,456,785 ordinary shares, can potentially dilute earnings per share in the future but have not been included in the calculation of diluted earnings per share because they are antidilutive for the periods presented.